Form 4 for TPST Tempest Therapeutics, Inc.
Accepted 2022-05-03 00:00:00 ET · period of report 2022-04-29 · accession 0000899243-22-016387 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-05-03 | 2022-04-29 | TPST | Woiwode Thomas | Dir, 10% | P - Purchase | $2.36 | +2.12M | 2.12M | New | +$5.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-29 | P | A | 2,118,644 | $2.36 | 2,118,644 | I See Footnote | — | — | (F2) These shares are held of record by Vantage II. Versant Vantage II GP, L.P. ("Vantage II GP") is the general partner of Vantage II, and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. |